A District Judge overturned last year’s jury verdict, declaring the application of Teva’s patents overly broad.
The biopharma giant’s decision to end its partnership with I-Mab follows it ending a trial for the drug early.
The UK-based surgical robotics company has now raised over $1bn in funding, cementing its unicorn status.
UK public sector doctor’s pay is below that in Germany or the US, and ongoing strike action may lead to more emigration.
Embattled biotech giant Illumina has led series A funding into genomics mapping company Broken String Biosciences.
Give your business an edge with our leading industry insights.
Global industry leaders are embracing ESG issues but diverging reporting standards pose a challenge to corporate sustainability.
Roche planned to launch the new formulation this year, but it will be pushed back after tweaks requested by FDA.
Kroger’s settlement, alongside the review of the Purdue Pharma bankruptcy case, is proof that the opioid reckoning isn’t over yet.
Mark Chadwick explains how the EU’s new ESG reporting regulation will impact pharmaceutical companies.
Sandoz, the generics division of Novartis, has underperformed in recent years, but the spin-off may not settle investors.